Previous 10 | Next 10 |
Verastem, Inc (VSTM) Q4 2019 Results Earnings Conference Call March 12, 2019 04:30 PM ET Company Participants Robert Forrester - CEO Rob Gagnon - Chief Financial Officer Joseph Lobacki - Chief Commercial Officer Dan Paterson - Chief Operating Officer Conference Call Partic...
Verastem Oncology (NASDAQ: VSTM ) Q4 highlights : More news on: Verastem, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Verastem (NASDAQ: VSTM ): Q4 GAAP EPS of -$0.37 beats by $0.17 . More news on: Verastem, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
U.S. Commercial Launch of COPIKTRA™ Underway $1.7 Million in 2018 Net Product Revenues from COPIKTRA Cash, Cash Equivalents and Short-Term Investments of $249.7 million as December 31, 2018 Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, (or “the ...
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following upcoming investor conferences: The...
In Subset of Patients with Relapsed or Refractory CLL/SLL Treated for Over 2 Years, Duvelisib Achieves 89% ORR and Median PFS of 40 Months DUO™ Crossover Extension Study Demonstrates 77% ORR and Median PFS of 15 Months in Patients with Relapsed or Refractory CLL/SLL Who Had Expe...
Infinity Pharmaceuticals ( INFI +4.3% ) inks an agreement with Healthcare Royalty Partners (HCR) monetizing certain royalties from COPIKTRA (duvelisib) sales by Verastem ( VSTM -1.6% ). More news on: Infinity Pharmaceuticals, Inc., Verastem, Inc., Healthcare stocks news, Rea...
Data Presented at the 23 rd Annual International Congress on Hematologic Malignancies COPIKTRA Demonstrates Progression-Free Survival of 16.4 Months and an Overall Response Rate of 78% in Adult Patients with CLL/SLL After At Least Two Prior Therapies Verastem, Inc. (Nasdaq:V...
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will host a conference call and webcast on...
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 8 th Annual SVB Leerink Global Healthcare Conference on F...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...